Here, we show that polyclonal MCPyV TAg specific CD4+T cells appropriate for ACT treatment of patients with VP-MCC can be generated in vitro from healthy donors using methods easily adaptable to clinical grade manufacture. This evidence concerns the gene CD4 and Merkel cell skin cancer.